291 related articles for article (PubMed ID: 15218393)
1. Crosslink breakers: a new approach to cardiovascular therapy.
Susic D; Varagic J; Ahn J; Frohlich ED
Curr Opin Cardiol; 2004 Jul; 19(4):336-40. PubMed ID: 15218393
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks.
Vasan S; Foiles P; Founds H
Arch Biochem Biophys; 2003 Nov; 419(1):89-96. PubMed ID: 14568012
[TBL] [Abstract][Full Text] [Related]
3. Breakers of advanced glycation end products restore large artery properties in experimental diabetes.
Wolffenbuttel BH; Boulanger CM; Crijns FR; Huijberts MS; Poitevin P; Swennen GN; Vasan S; Egan JJ; Ulrich P; Cerami A; Lévy BI
Proc Natl Acad Sci U S A; 1998 Apr; 95(8):4630-4. PubMed ID: 9539789
[TBL] [Abstract][Full Text] [Related]
4. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart.
Liu J; Masurekar MR; Vatner DE; Jyothirmayi GN; Regan TJ; Vatner SF; Meggs LG; Malhotra A
Am J Physiol Heart Circ Physiol; 2003 Dec; 285(6):H2587-91. PubMed ID: 12946933
[TBL] [Abstract][Full Text] [Related]
5. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes.
Forbes JM; Thallas V; Thomas MC; Founds HW; Burns WC; Jerums G; Cooper ME
FASEB J; 2003 Sep; 17(12):1762-4. PubMed ID: 12958202
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of C36, a novel breaker of advanced glycation endproducts cross-links, on the cardiovascular system of diabetic rats.
Cheng G; Wang LL; Long L; Liu HY; Cui H; Qu WS; Li S
Br J Pharmacol; 2007 Dec; 152(8):1196-206. PubMed ID: 17965740
[TBL] [Abstract][Full Text] [Related]
7. Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines.
Shapiro BP; Owan TE; Mohammed SF; Meyer DM; Mills LD; Schalkwijk CG; Redfield MM
Circulation; 2008 Sep; 118(10):1002-10. PubMed ID: 18711013
[TBL] [Abstract][Full Text] [Related]
8. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes.
Candido R; Forbes JM; Thomas MC; Thallas V; Dean RG; Burns WC; Tikellis C; Ritchie RH; Twigg SM; Cooper ME; Burrell LM
Circ Res; 2003 Apr; 92(7):785-92. PubMed ID: 12623881
[TBL] [Abstract][Full Text] [Related]
9. Collagen cross-link breakers: a beginning of a new era in the treatment of cardiovascular changes associated with aging, diabetes, and hypertension.
Susic D; Varagic J; Ahn J; Frohlich ED
Curr Drug Targets Cardiovasc Haematol Disord; 2004 Mar; 4(1):97-101. PubMed ID: 15032654
[TBL] [Abstract][Full Text] [Related]
10. AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats.
Yang S; Litchfield JE; Baynes JW
Arch Biochem Biophys; 2003 Apr; 412(1):42-6. PubMed ID: 12646266
[TBL] [Abstract][Full Text] [Related]
11. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process.
Bakris GL; Bank AJ; Kass DA; Neutel JM; Preston RA; Oparil S
Am J Hypertens; 2004 Dec; 17(12 Pt 2):23S-30S. PubMed ID: 15607432
[TBL] [Abstract][Full Text] [Related]
12. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.
Forbes JM; Yee LT; Thallas V; Lassila M; Candido R; Jandeleit-Dahm KA; Thomas MC; Burns WC; Deemer EK; Thorpe SR; Cooper ME; Allen TJ
Diabetes; 2004 Jul; 53(7):1813-23. PubMed ID: 15220206
[TBL] [Abstract][Full Text] [Related]
13. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension.
Zieman SJ; Melenovsky V; Clattenburg L; Corretti MC; Capriotti A; Gerstenblith G; Kass DA
J Hypertens; 2007 Mar; 25(3):577-83. PubMed ID: 17278974
[TBL] [Abstract][Full Text] [Related]
14. Advanced glycation end product cross-linking: pathophysiologic role and therapeutic target in cardiovascular disease.
Zieman S; Kass D
Congest Heart Fail; 2004; 10(3):144-9; quiz 150-1. PubMed ID: 15184729
[TBL] [Abstract][Full Text] [Related]
15. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease.
Zieman SJ; Kass DA
Drugs; 2004; 64(5):459-70. PubMed ID: 14977384
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular and renal effects of a collagen cross-link breaker (ALT 711) in adult and aged spontaneously hypertensive rats.
Susic D; Varagic J; Ahn J; Frohlich ED
Am J Hypertens; 2004 Apr; 17(4):328-33. PubMed ID: 15062886
[TBL] [Abstract][Full Text] [Related]
17. Treating diastolic heart failure with AGE crosslink breakers: thinking outside the heart failure box.
Redfield MM
J Card Fail; 2005 Apr; 11(3):196-9. PubMed ID: 15812747
[No Abstract] [Full Text] [Related]
18. Therapeutic effect of green tea extract on advanced glycation and cross-linking of collagen in the aorta of streptozotocin diabetic rats.
Babu PV; Sabitha KE; Shyamaladevi CS
Clin Exp Pharmacol Physiol; 2006 Apr; 33(4):351-7. PubMed ID: 16620300
[TBL] [Abstract][Full Text] [Related]
19. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes.
Aronson D
J Hypertens; 2003 Jan; 21(1):3-12. PubMed ID: 12544424
[TBL] [Abstract][Full Text] [Related]
20. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker.
Kass DA; Shapiro EP; Kawaguchi M; Capriotti AR; Scuteri A; deGroof RC; Lakatta EG
Circulation; 2001 Sep; 104(13):1464-70. PubMed ID: 11571237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
